Form 8-K - Current report:
SEC Accession No. 0001193125-25-137032
Filing Date
2025-06-06
Accepted
2025-06-06 16:02:30
Documents
13
Period of Report
2025-06-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d926935d8k.htm   iXBRL 8-K 46984
2 EX-3.1 d926935dex31.htm EX-3.1 5251
  Complete submission text file 0001193125-25-137032.txt   174153

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tngx-20250605.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tngx-20250605_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tngx-20250605_pre.xml EX-101.PRE 11707
15 EXTRACTED XBRL INSTANCE DOCUMENT d926935d8k_htm.xml XML 3843
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39485 | Film No.: 251030460
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)